Tourette Syndrome-Pipeline Review, H1 2015

Tourette Syndrome-Pipeline Review, H1 2015

  • Products Id :- GMDHC6189IDB
  • |
  • Pages: 78
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Tourette Syndrome-Pipeline Review, H1 2015


Global Markets Direct's, 'Tourette Syndrome-Pipeline Review, H1 2015', provides an overview of the Tourette Syndrome's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Tourette Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tourette Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Tourette Syndrome

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Tourette Syndrome and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Tourette Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Tourette Syndrome pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Tourette Syndrome

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Tourette Syndrome pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Tourette Syndrome Overview 7

Therapeutics Development 8

Pipeline Products for Tourette Syndrome-Overview 8

Pipeline Products for Tourette Syndrome-Comparative Analysis 9

Tourette Syndrome-Therapeutics under Development by Companies 10

Tourette Syndrome-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Unknown Stage Products 14

Tourette Syndrome-Products under Development by Companies 15

Tourette Syndrome-Companies Involved in Therapeutics Development 16

AstraZeneca PLC 16

Auspex Pharmaceuticals, Inc. 17

Catalyst Pharmaceutical Partners, Inc. 18

Edison Pharmaceuticals, Inc. 19

Neurocrine Biosciences, Inc. 20

Otsuka Holdings Co., Ltd. 21

Psyadon Pharmaceuticals, Inc. 22

Reviva Pharmaceuticals Inc. 23

Synchroneuron Inc. 24

Tourette Syndrome-Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 33

acamprosate calcium SR-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

aripiprazole-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

AZD-5213-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

CPP-115-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

dutetrabenazine ER-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

ecopipam hydrochloride-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

RP-5063-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

valbenazine-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

vatiquinone-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

vigabatrin-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Tourette Syndrome-Recent Pipeline Updates 51

Tourette Syndrome-Dormant Projects 69

Tourette Syndrome-Discontinued Products 70

Tourette Syndrome-Product Development Milestones 71

Featured News & Press Releases 71

Jan 14, 2015: Auspex Pharmaceuticals Receives FDA Orphan Drug Designation of SD-809 for Treatment of Tourette Syndrome in the Pediatric Population 71

Oct 02, 2014: Neurocrine Announces Expansion Of VMAT2 Inhibitor Program With Initiation Of Tourette Syndrome Clinical Study 71

May 28, 2014: Psyadon Announces the Opening of a New Clinical Trial of Ecopipam for the Treatment of Tourette's Syndrome in Children Ages 7-17 72

Jul 24, 2012: Psyadon Announces Positive Interim Analysis Of Phase II Study Of Ecopipam For Treatment Of Tourette Syndrome 73

Sep 19, 2011: Neurocrine Biosciences Initiates Phase II Clinical Trial Of NBI-98854 74

May 11, 2011: Tourette Syndrome Association And Psyadon Pharma To Collaborate On Drug Trial For Tourette Syndrome Treatment 75

Dec 16, 2010: Otsuka Announces Defendants Appeal From Final Judgment In US Abilify Patent Litigation 75

Nov 16, 2010: Otsuka Prevails In US Abilify Patent Litigation 75

Apr 13, 2010: Neurocrine Biosciences Begins Second VMAT2 Phase I Clinical Trial 76

Appendix 77

Methodology 77

Coverage 77

Secondary Research 77

Primary Research 77

Expert Panel Validation 77

Contact Us 77

Disclaimer 78

List of Tables

Number of Products under Development for Tourette Syndrome, H1 2015 8

Number of Products under Development for Tourette Syndrome-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Unknown Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Tourette Syndrome-Pipeline by AstraZeneca PLC, H1 2015 16

Tourette Syndrome-Pipeline by Auspex Pharmaceuticals, Inc., H1 2015 17

Tourette Syndrome-Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2015 18

Tourette Syndrome-Pipeline by Edison Pharmaceuticals, Inc., H1 2015 19

Tourette Syndrome-Pipeline by Neurocrine Biosciences, Inc., H1 2015 20

Tourette Syndrome-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 21

Tourette Syndrome-Pipeline by Psyadon Pharmaceuticals, Inc., H1 2015 22

Tourette Syndrome-Pipeline by Reviva Pharmaceuticals Inc., H1 2015 23

Tourette Syndrome-Pipeline by Synchroneuron Inc., H1 2015 24

Assessment by Monotherapy Products, H1 2015 25

Number of Products by Stage and Target, H1 2015 27

Number of Products by Stage and Mechanism of Action, H1 2015 29

Number of Products by Stage and Route of Administration, H1 2015 31

Number of Products by Stage and Molecule Type, H1 2015 32

Tourette Syndrome Therapeutics-Recent Pipeline Updates, H1 2015 51

Tourette Syndrome-Dormant Projects, H1 2015 69

Tourette Syndrome-Discontinued Products, H1 2015 70

List of Figures

Number of Products under Development for Tourette Syndrome, H1 2015 8

Number of Products under Development for Tourette Syndrome-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 13

Assessment by Monotherapy Products, H1 2015 25

Number of Products by Top 10 Targets, H1 2015 26

Number of Products by Stage and Top 10 Targets, H1 2015 26

Number of Products by Top 10 Mechanism of Actions, H1 2015 28

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 28

Number of Products by Top 10 Routes of Administration, H1 2015 30

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 30

Number of Products by Stage and Top 10 Molecule Types, H1 2015 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

AstraZeneca PLC

Auspex Pharmaceuticals, Inc.

Catalyst Pharmaceutical Partners, Inc.

Edison Pharmaceuticals, Inc.

Neurocrine Biosciences, Inc.

Otsuka Holdings Co., Ltd.

Psyadon Pharmaceuticals, Inc.

Reviva Pharmaceuticals Inc.

Synchroneuron Inc.

Tourette Syndrome Therapeutic Products under Development, Key Players in Tourette Syndrome Therapeutics, Tourette Syndrome Pipeline Overview, Tourette Syndrome Pipeline, Tourette Syndrome Pipeline Assessment

select a license

Single User License
USD 2000 INR 133860
Site License
USD 4000 INR 267720
Corporate User License
USD 6000 INR 401580



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]